Favorable long-term safety profile demonstrated for Ilumetri

9 February 2021

Spanish dermatology specialist Almirall (ALM: MC) today announced the publication in the British Journal of Dermatology (BJD) of a full five-year pooled data analysis from two Phase III clinical studies, reSURFACE 1 and reSURFACE 2 of Ilumetri (tildrakizumab), an interleukin (IL)-23p19 inhibitor for the treatment of moderate-to-severe plaque psoriasis.

These data provide evidence of sustained efficacy in tildrakizumab responders and in patients switched from etanercept to tildrakizumab at week 28, and a favorable long-term safety profile with total tildrakizumab exposure of over 5,400 patient-years, said Almirall. During this period, PASI and PGA response rates were maintained in a large proportion of patients. This is the first and longest complete dataset published in a medical journal on an anti-IL23p19 inhibitor.

Long-term control of psoriasis

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK